The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
- 1Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
- 2Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Nanjing, China
- 3The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
- 4Department of Pediatric Surgery, Sanya Women and Children’s Hospital, Sanya, China
- 5Department of Cardio-Thoracic Surgery, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
A Corrigendum on
The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
By Pan T, Tuoerxun T, Chen X,Yang C-J, Jiang C-Y, Zhu Y-F, Li Z-S, Jiang X-Y, Zhang H-T, Zhang H, Wang Y-P, Chen W, Lu L-C, Ge M, Cheng Y-Q, Wang D-J and Zhou Q (2023) Front. Immunol. 14:1082830. doi: 10.3389/fimmu.2023.1082830
In the published article, there was an error in Figures 4B–D as published. The blue lines were mistakenly identified as the Sivelestat group and the red lines were mistakenly identified as the Control group. The corrected Figure 4 and its caption “(A) The oxygen index (PaO2/FiO2), P<0.01; ※:P< 0.05, †:P> 0.05. (B) The procalcitonin, P<0.01; ※:P< 0.05, †:P> 0.05. (C) The interleukin-6, P=0.02; ※:P< 0.05, †:P> 0.05. (D) The C reactive protein, P<0.01; ※:P< 0.05, †:P> 0.05.” appear below.
Figure 4 (A) The oxygen index (PaO2/FiO2), P < 0.01; ※:P < 0.05, †:P > 0.05. (B) The procalcitonin, P < 0.01; ※:P < 0.05, †:P > 0.05. (C) The interleukin-6, P=0.02; ※:P < 0.05, †:P > 0.05. (D) The C reactive protein, P < 0.01; ※:P < 0.05, †:P > 0.05.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: sivelestat, cardiopulmonary bypass, acute lung injury, cardiovascular surgery, outcomes
Citation: Pan T, Tuoerxun T, Chen X, Yang C-J, Jiang C-Y, Zhu Y-F, Li Z-S, Jiang X-Y, Zhang H-T, Zhang H, Wang Y-P, Chen W, Lu L-C, Ge M, Cheng Y-Q, Wang D-J and Zhou Q (2023) Corrigendum: The neutrophil elastase inhibitor, Sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass. Front. Immunol. 14:1165081. doi: 10.3389/fimmu.2023.1165081
Received: 13 February 2023; Accepted: 21 February 2023;
Published: 01 March 2023.
Edited and Reviewed by:
Ping Yuan, Tongji University, ChinaCopyright © 2023 Pan, Tuoerxun, Chen, Yang, Jiang, Zhu, Li, Jiang, Zhang, Zhang, Wang, Chen, Lu, Ge, Cheng, Wang and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dong-Jin Wang, dongjin_wang@126.com; Qing Zhou, zhouqing@njglyy.com; Yong-Qing Cheng, cyq197549@sina.com
†These authors have contributed equally to this work and share first authorship